Incyte Corporation (INCY) Reports First-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs
5/2/2013 8:14:13 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Incyte Corporation (Nasdaq: INCY) today reported first-quarter 2013 financial results, including revenue from Jakafi® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also updated information about key clinical programs.
Help employers find you! Check out all the jobs and post your resume.